Key terms
About IDYA
IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The firm focuses on the targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically defined cancers having GNAQ or GNA11 gene mutations. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest IDYA news
Apr 05
6:01am ET
Ideaya Biosciences announces inducement grants under Nasdaq listing rule
Mar 25
11:25am ET
Ideaya Biosciences participates in a conference call with JPMorgan
Mar 25
10:57am ET
Ideaya Biosciences participates in a conference call with JPMorgan
Mar 21
6:20am ET
Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL), IDEAYA Biosciences (IDYA) and Vor Biopharma (VOR)
Mar 21
6:08am ET
Ideaya Biosciences price target raised to $60 from $40 at Citi
Mar 13
11:15am ET
Strong Buy Rating for IDEAYA Biosciences Based on Strategic Partnership and Promising Oncology Pipeline
Mar 12
6:33am ET
Ideaya enters supply agreement with Merck to evaluate IDE161, Keytruda
Mar 08
9:40am ET
GE upgraded, Vail Resorts downgraded: Wall Street’s top analyst calls
Mar 08
5:08am ET
Ideaya Biosciences initiated with a Buy at BTIG
Feb 25
11:40pm ET
Analysts Are Bullish on These Healthcare Stocks: IDEAYA Biosciences (IDYA), Insulet (PODD)
Feb 22
7:54am ET
Analysts Are Bullish on These Healthcare Stocks: Olema Pharmaceuticals (OLMA), IDEAYA Biosciences (IDYA)
Feb 21
7:49am ET
Ideaya Biosciences price target raised to $53 from $43 at RBC Capital
Feb 20
3:23pm ET
Ideaya Biosciences price target raised to $50 from $40 at Oppenheimer
Feb 20
6:11am ET
Ideaya Biosciences reports Q4 EPS (52c), consensus (47c)
Feb 13
9:10pm ET
Analysts’ Top Healthcare Picks: Illumina (ILMN), IDEAYA Biosciences (IDYA)
Feb 09
8:28am ET
IDEAYA Biosciences (IDYA) Gets a Buy from Stifel Nicolaus
Jan 24
3:00am ET
IDEAYA Biosciences Launches At-The-Market Offering Program
Jan 17
7:38am ET
JPMorgan ups Ideaya target, adds to Analyst Focus List
Jan 10
7:03am ET
Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), IDEAYA Biosciences (IDYA) and Surgery Partners (SGRY)
No recent press releases are available for IDYA
IDYA Financials
Key terms
Ad Feedback
IDYA Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
IDYA Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
